BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 19775621)

  • 1. p53: balancing tumour suppression and implications for the clinic.
    Buganim Y; Rotter V
    Eur J Cancer; 2009 Sep; 45 Suppl 1():217-34. PubMed ID: 19775621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of genetic instability by gain-of-function p53 cancer mutants.
    Xu Y
    Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tumor suppressor genes: mutations in RB and p53 genes are significant carcinogenic factors].
    Wiman KG
    Lakartidningen; 1992 Sep; 89(39):3169-74. PubMed ID: 1405928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 mutation heterogeneity in cancer.
    Soussi T; Lozano G
    Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein.
    Harris MP; Sutjipto S; Wills KN; Hancock W; Cornell D; Johnson DE; Gregory RJ; Shepard HM; Maneval DC
    Cancer Gene Ther; 1996; 3(2):121-30. PubMed ID: 8729911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy.
    Wang XW; Harris CC
    Cancer Surv; 1996; 28():169-96. PubMed ID: 8977035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New transcription factor-based cancer therapy. Gene therapy, cell lysis, reactivation of p53 are the new approaches].
    Wiman KG
    Lakartidningen; 1997 Sep; 94(38):3268-72. PubMed ID: 9379794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p53 tumour suppressor gene.
    Steele RJ; Thompson AM; Hall PA; Lane DP
    Br J Surg; 1998 Nov; 85(11):1460-7. PubMed ID: 9823903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The p53 tumour suppressor gene and product.
    Levine AJ
    Cancer Surv; 1992; 12():59-79. PubMed ID: 1638548
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis.
    Chang F; Syrjänen S; Kurvinen K; Syrjänen K
    Am J Gastroenterol; 1993 Feb; 88(2):174-86. PubMed ID: 8424417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 mutants without a functional tetramerisation domain are not oncogenic.
    Chène P; Bechter E
    J Mol Biol; 1999 Mar; 286(5):1269-74. PubMed ID: 10064694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [p53 as a molecular target for cancer therapy].
    Ishioka C; Osada M; Gamo M; Kanamaru R
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
    Greenblatt MS; Bennett WP; Hollstein M; Harris CC
    Cancer Res; 1994 Sep; 54(18):4855-78. PubMed ID: 8069852
    [No Abstract]   [Full Text] [Related]  

  • 16. Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells.
    Donninger H; Binder A; Bohm L; Parker MI
    Biol Chem; 2008 Jan; 389(1):57-67. PubMed ID: 18095870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gain-of-function mutations in the tumor suppressor gene p53.
    van Oijen MG; Slootweg PJ
    Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The properties of p53 proteins selected for the loss of suppression of transformation.
    Olson DC; Levine AJ
    Cell Growth Differ; 1994 Jan; 5(1):61-71. PubMed ID: 8123594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of mutant p53 in human cancer.
    Goh AM; Coffill CR; Lane DP
    J Pathol; 2011 Jan; 223(2):116-26. PubMed ID: 21125670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.